HEALTH

FDA clears Abbott’s FreeStyle InsuLinx blood-glucose monitoring system

BY Allison Cerra

ALAMEDA, Calif. — A blood-glucose monitoring system created by Abbott has received clearance from the Food and Drug Administration.

Abbott said the FDA has approved the FreeStyle InsuLinx blood-glucose monitoring system, which includes a touchscreen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. What’s more, the device also is equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their healthcare providers.

"The new FreeStyle InsuLinx System represents Abbott’s latest advancement in delivering innovative products for people with diabetes who use insulin," Abbott Diabetes Care SVP Heather Mason said. "The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States."

The FreeStyle InsuLinx aystem will be available to U.S. consumers within the coming months.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Hi-Tech Pharmacal buys homeopathic product line from Dynova Labs

BY Alaric DeArment

AMITYVILLE, N.Y. — Drug maker Hi-Tech Pharmacal has bought a line of homeopathic nasal spray products from Dynova Labs, the company said Thursday.

Hi-Tech announced the acquisition of Sinus Buster and Allergy Buster for $1.25 million and an addition $1.25 million that it will deposit in an escrow account. The company also will pay Dynova a royalty on net sales for up to three and a half years or up to $1.75 million. The products, which Hi-Tech will sell through its Health Care Products over-the-counter division, had sales of $3.3 million in 2011.

"With the addition of these products, we are well-positioned to benefit from the growing trend toward natural, homeopathic treatment options," Hi-Tech president and CEO David Seltzer said. "These brands create a good strategic fit for Health Care Products as we expand our presence in the cough-cold and allergy categories."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Hyland’s showcases adult cough-cold medicines at ECRM show

BY Michael Johnsen

LAS VEGAS — Hyland’s has extended its Defend lineup of cough-cold products with a pair of adult cough syrups — Defend Cough & Cold and Defend Cough & Cold Night — last week at the ECRM Cough & Cold and Allergy EPPS.

The products, which carry a suggested retail price of $9.99, are being promoted through Hyland’s "Action Moms" campaign, an interactive campaign that ties Hyland’s adult cough-cold products to a key target demographic: the do-everything mom.

Hyland’s already is well on its way to cracking the top 10 branded list of cold/allergy/sinus liquids and powders, as captured by SymphonyIRI Group. For the 52 weeks ended Feb. 19, sales of Hyland’s liquids were up 113.5% to $10.8 million and ranked No. 13 (excluding private label) across food, drug and mass (minus Walmart) outlets.

Following its week in Las Vegas, Hyland’s made its way to Anaheim, Calif. March 9 to showcase all of its new offerings at the Natural Products Expo West. The company provided its Facebook fans a sneak peek at next week’s preparations with a video that can be viewed here.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?